Renal fibrosis is a common pathological feature of chronic kidney diseases (CKDs), driven by excessive extracellular matrix (ECM) accumulation. Despite its prevalence, therapeutic candidates specifically targeting fibrosis are limited, and the role of renal tubular epithelial cells in fibrosis pathogenesis remains unclear. In this study, we evaluated the anti-fibrotic effects of Plumbagin, a plant-derived natural compound, using a folic acid-induced renal fibrosis model that simulates proximal tubular injury-driven fibrosis. Plumbagin treatment significantly attenuated renal fibrosis in a folic acid-induced model. Furthermore, using the human proximal tubular epithelial cell line HK-2, we assessed EMT, a key fibrosis-promoting biological process, and the expression of fibrosis-related factors. Plumbagin treatment reduced TGF-β-induced EMT and fibrosis-related factor expression in HK-2 cells. In summary, Plumbagin suppresses EMT in renal tubular epithelial cells under fibrotic conditions and alleviates renal fibrosis. These findings highlight the potential of Plumbagin as a therapeutic drug for renal fibrosis and propose a shared therapeutic strategy for CKD patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2025.151325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plumbagin ameliorates renal fibrosis by suppressing epithelial-mesenchymal transition.
Biochem Biophys Res Commun
January 2025
Department of Biomedical Laboratory Science, Yonsei University MIRAE Campus, Wonju, 26493, South Korea. Electronic address:
Renal fibrosis is a common pathological feature of chronic kidney diseases (CKDs), driven by excessive extracellular matrix (ECM) accumulation. Despite its prevalence, therapeutic candidates specifically targeting fibrosis are limited, and the role of renal tubular epithelial cells in fibrosis pathogenesis remains unclear. In this study, we evaluated the anti-fibrotic effects of Plumbagin, a plant-derived natural compound, using a folic acid-induced renal fibrosis model that simulates proximal tubular injury-driven fibrosis.
View Article and Find Full Text PDFmTOR/p70S6K signaling pathway promotes fibrillin-1 expression in AKI-to-CKD transition post CA/CPR.
Cell Signal
January 2025
School of Basic Medicine, Jiamusi University, Jiamusi 154007, PR China. Electronic address:
The possible involvement of mTOR/p70S6K signaling in mediating Fibrillin-1 expression during the transition from acute kidney injury (AKI) to chronic kidney disease (CKD) after cardiac arrest and cardiopulmonary resuscitation (CA/CPR). A CA/CPR AKI model was established using male C57BL/6 mice aged 8-12 weeks. The expression of Fibrillin-1 and activation of the mTOR/p70S6K signaling pathway in kidney tissues were assessed at different time points.
View Article and Find Full Text PDFSenolytic procyanidin C1 alleviates renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells.
FASEB J
January 2025
Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Renal fibrosis is a common pathological process in various chronic kidney diseases. The accumulation of senescent renal tubular epithelial cells (TECs) in renal tissues plays an important role in the development of renal fibrosis. Eliminating senescent TECs has been proven to effectively reduce renal fibrosis.
View Article and Find Full Text PDFUrinary Endotrophin and Long-term Outcomes in Kidney Transplant Recipients.
Transplant Direct
March 2024
Department of Nephrology, Odense University Hospital, Odense, Denmark.
Background: Kidney fibrosis is a suggested cause of kidney failure and premature mortality. Because collagen type VI is closely linked to kidney fibrosis, we aimed to evaluate whether urinary endotrophin, a collagen type VI fragment, is associated with graft failure and mortality among kidney transplant recipients (KTR).
Methods: In this prospective cohort study, KTR with a functioning graft ≥1-y posttransplantation were recruited; 24-h urinary endotrophin excretion was measured using an ELISA method.
Current status and prospects of traditional Chinese medicine combined with stem cell therapy for chronic kidney disease.
Front Pharmacol
January 2025
Division of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Renal fibrosis is one of the main pathological features of chronic kidney disease (CKD), and its treatment has been a hot research topic. Recent studies have shown that stem cell therapy can repair renal pathological changes and slow the progression of CKD. In addition, a large number of experiments have confirmed that traditional Chinese medicine (TCM), especially Chinese medicine compound preparations, has the advantage of multitargeting interventions to improve renal fibrosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!